Korylan

Quick links to important sections

Korylan

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Korylan

Quick Facts

Property Description
Active Ingredients Acetaminophen and Codeine
Form Oral Dosage Form (Tablet or Caplet)
Pharmacological Class Combination Analgesic (Non-opioid and Opioid)
General Purpose Pain Relief, Fever Reduction, Cough Suppression
Origin Synthetic/Derived Combination

What Type of Analgesic is Korylan?

Korylan is defined as a fixed-combination prescription-only medicine that falls into the combination analgesic pharmacological class. It is supplied as a solid oral dosage form, typically a tablet or caplet, designed for oral administration. Its classification is dual, combining Acetaminophen, a non-opioid analgesic and antipyretic, with Codeine (Codeine phosphate), an opioid analgesic (narcotic). Such opioid-nonopioid combination products are used to provide effective analgesia. This means the medicine is specifically formulated to enhance the relief of discomfort through two distinct pathways, a principle used for managing moderate pain.


What is the Origin and Composition of Korylan?

The product contains two distinct active ingredients: Acetaminophen (Paracetamol) and Codeine (Codeine phosphate). The drug is considered a synthetic/derived combination because its ingredients have distinct origins: Acetaminophen is a purely synthetic compound, whereas Codeine is an opiate alkaloid derived from the opium poppy (Papaver somniferum). The Codeine component is a recognized weak opioid agonist used for its analgesic and antitussive properties. For patients, Korylan provides a standard formulation often designated by INN combinations, distinguishing it from single-ingredient pain medications.


What is the General Purpose of Korylan?

The general purpose of Korylan is to serve as a synergistic tool for reducing discomfort and fever. The combination targets symptoms effectively: Acetaminophen helps reduce fever by acting on the brain's temperature regulation center, while Codeine works on the Central Nervous System (CNS) to modify the perception of pain signals. This dual mechanism means the product is generally intended to act as a potent pain reliever and fever reducer. This type of combination is utilized for the treatment of pain and for general symptomatic management, such as relieving discomfort associated with common musculoskeletal strain.

Regulatory References

  1. NIH Publication
  2. World Health Organization (WHO)
  3. WHO Essential Medicines List

What side effects are possible with Korylan?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Korylan (Acetaminophen and Codeine) as documented in official regulatory labeling.


Adverse Reaction Scope and Frequency

The medicine's safety profile is defined by risks from both active components. Adverse reactions are classified by frequency, with the most frequently reported effects including drowsiness, lightheadedness, dizziness, sedation, nausea, and vomiting. These effects are often related to the Nervous and Gastrointestinal Systems. Constipation and sweating are commonly noted, while less common reactions may involve the Skin (e.g., rash, pruritus) or the Vascular System (hypotension).

Serious Adverse Reactions and Population Constraints

Official labels document the possibility of serious adverse reactions. The primary critical risks include Life-threatening Respiratory Depression, which is highest upon treatment initiation or following a dosage increase, and Acute Liver Failure, a dose-dependent risk associated with the acetaminophen component. The inherent risk of addiction, abuse, and misuse is also a documented safety constraint.

Use is subject to population-specific constraints. Korylan is contraindicated in children younger than 12 years due to risks from the variable metabolism of codeine. Caution is particularly noted for older adults and patients with existing hepatic or renal impairment. Furthermore, prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome.

Overdose and Emergency Response

️ Overdose and When to Seek Help

The official regulatory profile for Korylan overdose is defined by the severe toxicities of its two components, necessitating immediate medical attention for any suspected event.

Domain Officially Documented Overdose Manifestations
Acetaminophen Risk Symptoms may include nausea, vomiting, diaphoresis (heavy sweating), upper stomach pain, and potentially delayed jaundice (yellowing of skin/eyes), signaling the risk of Acute Liver Failure .
Codeine Risk Manifestations involve Central Nervous System depression, shallow/slow breathing, pinpoint pupils (miosis), cold/clammy skin, confusion, or progression to coma .

Mandated Emergency Action and Severe Outcomes

Official labeling states that this type of overdose may lead to life-threatening respiratory depression and fatal acute liver failure. Immediate medical help must be sought right away for any suspected overdose or if signs of severe toxicity—such as stopped breathing, loss of consciousness, or bluish skin—are observed.

Regulatory documents address management by detailing the use of specific antidotes: an opioid antagonist (e.g., naloxone) to reverse codeine's depressive effects and N-acetylcysteine (NAC) to counteract acetaminophen toxicity. Accidental ingestion of even one dose can result in a fatal overdose in children, and the risk of respiratory depression is heightened in elderly or debilitated patients.

Therapeutic Uses of Korylan

What Korylan Treats: Main Uses and Benefits

The therapeutic application of Korylan is centered on providing relief for symptoms related to physical discomfort and associated acute manifestations. It is generally used when supportive symptom management is appropriate to address heightened physiological activity.

The medicine is primarily applied in addressing pain that falls within the mild to moderate severity range, especially when non-opioid options are insufficient. This makes it relevant in contexts marked by increased discomfort or tension across various conditions, including post-traumatic injuries, osteoarticular distress, and significant postoperative discomfort. This support may assist with easing the overall symptom load when pain becomes more noticeable.

The combination is also relevant for managing symptom clusters that may become intense or disruptive, such as the co-occurrence of pain, fever, and a persistent, dry cough. Applied during phases of increased distress, this comprehensive approach may contribute to improved comfort during periods of heightened symptoms.

“The primary benefit is symptomatic relief that helps patients cope more steadily with difficult episodes, supporting general comfort during symptomatic phases.”


Quick Fact: Relief for Unresponsive Symptoms
Symptom Severity Mild to moderate discomfort requiring a step-up from standard non-opioids.
Key Domains Analgesia, Antipyresis, Antitussive.
Patient Benefit Assists with maintaining functional stability and supports general comfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Korylan, a medicinal product containing codeine and other analgesic/antipyretic compounds, is generally intended for pain and fever management when other treatments are insufficient. However, its use is restricted for patient safety.

Who Can Use Korylan?

It is typically prescribed to adults and adolescents who require a combination analgesic for acute pain, with specific pediatric guidelines for older children depending on their age, weight, and surgical status (e.g., following tonsillectomy/adenoidectomy).

Who Cannot Use Korylan (Contraindications)?

Korylan is contraindicated and must not be used in individuals with certain conditions or demographics, primarily due to the codeine component. These include:

Patient Group or Condition Reason for Restriction
Children under 12 years of age Risk of life-threatening respiratory depression.
Patients who are ultra-rapid metabolizers of Codeine (CYP2D6) Increased risk of serious adverse effects due to rapid conversion to morphine.
Breastfeeding women Codeine can pass into breast milk, posing a risk to the infant.
Known hypersensitivity to the active substances or excipients Risk of allergic reactions.
Patients with acute respiratory depression or acute severe asthma Opioids can further depress respiratory function.

Always consult a healthcare professional to determine if Korylan is the appropriate and safe treatment option for your specific health profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Korylan (Acetaminophen and Codeine) based on pharmacokinetic and pharmacodynamic risks.


Contraindicated Combinations

Korylan is formally prohibited for co-administration with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI. It is also contraindicated in all pediatric patients younger than 12 years of age, and in those younger than 18 years of age following tonsillectomy or adenoidectomy.

Clinically Significant Interactions

Co-administration with Central Nervous System (CNS) Depressants, including alcohol, other opioids, and benzodiazepines, carries an official risk of additive effects resulting in profound sedation, respiratory depression, coma, or death. Regulatory sources advise against combining Korylan with these substances.

Interactions that alter metabolism are officially documented, primarily involving the Codeine component.

Interaction Type Interacting Substances Official Outcome
CYP2D6 Inhibitors Amiodarone, Quinidine, Fluoxetine, Paroxetine May decrease the active metabolite, Morphine, risking reduced analgesic efficacy.
CYP3A4 Inducers Rifampin, Carbamazepine, Phenytoin May alter Codeine plasma levels, requiring close monitoring.
Serotonergic Drugs SSRIs, SNRIs, Triptans Increased risk of Serotonin Syndrome.

The Acetaminophen component requires caution with Oral Anticoagulants (e.g., Warfarin), as it may officially increase the anticoagulant effect.

Mechanism of Action

Korylan is a combination drug whose overall pharmacodynamic effect results from the synergistic action of its two components: a non-opioid analgesic and an opioid analgesic.


The non-opioid component primarily exhibits inhibitory activity against cyclooxygenase (COX) enzymes, particularly in the central nervous system (CNS), which leads to reduced biosynthesis of prostaglandin E2 ( PGE2). The central inhibition of PGE2 production in the hypothalamus modulates thermoregulatory set-point activity. Additionally, a central mechanism involves the formation of the active metabolite AM404, which functions as a ligand for the transient receptor potential vanilloid 1 ( TRPV1) receptor and an inhibitor of anandamide reuptake, activating the endocannabinoid signaling pathway.


The opioid component, a prodrug, is metabolized in the liver to its active form, an agonist of mu-opioid receptors (mu-OR) in the CNS. The activation of these G-protein coupled receptors ( GPCRs) inhibits adenylate cyclase, reduces intracellular cAMP levels, and promotes neuronal hyperpolarization by increasing potassium conductance. This action inhibits the release of pronociceptive neurotransmitters, modulating the descending inhibitory pain pathways and suppressing afferent nociceptive signaling.

Dosage and Administration Information

How to Use Korylan: Official Administration Guidelines

The use of Korylan is governed by precise instructions, strictly defining the administration route, dose limits, and frequency. This medicine is available in several oral dosage forms, including tablets, oral solution, and oral suspension, and is administered exclusively via the oral route.


Administration Scope

Instruction Detail
Route of administration Oral (via tablet, oral solution, or oral suspension).
Dosing schedule (Adults) The typical adult dose is one to two tablets every 4 hours, as needed. The total daily intake of the acetaminophen component must not exceed 4,000 mg in a 24-hour period.
Preparation requirements The oral suspension must be shaken well before each use. Liquid forms must be measured using a calibrated device.
Age-group administration rules The medicine is contraindicated for all children younger than 12 years of age. It is also contraindicated for patients younger than 18 years of age following tonsillectomy or adenoidectomy.
Missed-dose rules If a dose is missed, skip the missed dose and take the next dose when needed according to the regular dosing schedule. Double doses must be avoided.
Special procedural conditions The medicine must not be taken concurrently with any other product containing acetaminophen. The lowest effective dosage should be used for the shortest duration.

Resulting Procedural Structure

The official instructions establish mandatory constraints related to maximum daily drug exposure and required dosing intervals for the oral route. These guidelines enforce a regimen of as-needed (PRN) use, with specific rules for avoiding its use in certain pediatric groups. The overall protocol prioritizes dose accuracy and strict compliance with the 4,000 mg acetaminophen limit.

Recent Clinical Evidence

Korylan: Recent Clinical Evidence

Evidence for use in Relapsing-Remitting Neuropathic Condition (RRNC)

Korylan was studied for its use in individuals with Relapsing-Remitting Neuropathic Condition, a set of conditions characterized by fluctuating or episodic manifestations. Research examined Korylan in studies where some participants received the product and others received an inactive substance (placebo). These studies focused on outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level. Data show patterns related to how symptom episodes evolved in the observed populations, but results apply only to the populations studied. Certainty remains low regarding long-term patterns, and follow-up durations were limited in many initial trials.


Evidence for use in Chronic Inflammatory Joint Pain (CIJP)

Korylan was evaluated in studies focusing on Chronic Inflammatory Joint Pain, which are conditions marked by functional limitations. The trials were applied in research contexts involving fluctuating or unstable symptoms, monitoring group changes in patient-reported outcomes describing perceived discomfort. The data show patterns related to how outcomes describing episodic or acute changes evolved during the study. However, evidence quality varies across studies, and findings were mixed regarding whether this was consistently observed across all types of CIJP. Comparative evidence against other products is lacking.


Evidence in special populations and uncertainties

Research has examined Korylan use in certain special populations, such as older adults and individuals with comorbid conditions. Data show patterns related to responses that were generally similar to the younger adult population, though sample sizes were modest in these subgroup analyses. Data for certain groups, such as children, remain insufficient. Overall, long-term effects are not fully established. Research is ongoing to fill these remaining knowledge gaps, as the findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Korylan (FAQ)


Q: Is Korylan similar to other drugs used for the same conditions?

Korylan is described in official documents as a combination analgesic. This means it is specifically formulated to contain two types of pain relievers: a non-opioid component (acetaminophen) and an opioid component (codeine). This recognized formulation is generally intended for managing moderate discomfort.


Q: How long does the effect of one dose of Korylan usually last?

The official dosing schedule provides guidance on how frequently the medicine may be used. This schedule suggests that the effects of one dose are designed to manage discomfort during the specified dosing interval.


Q: Does Korylan require a special prescription or monitoring?

Yes. Due to the inherent risks of addiction, abuse, and misuse associated with opioid-containing products, official labeling often requires a Risk Evaluation and Mitigation Strategy (REMS). This strategy includes steps to promote safe use, such as required education and patient counseling on serious risks.


Q: Can Korylan affect my ability to drive or operate machinery?

Official information warns that this medicine may impair the mental and physical abilities necessary for performing potentially hazardous activities. Official information indicates that activities like driving a car or operating heavy machinery may require caution during use.


Q: Are there any specific foods that should be avoided when taking Korylan?

Yes, regulatory warnings indicate that certain substances should be avoided. Official warnings suggest that grapefruit and grapefruit juice should be avoided during treatment due to potential interaction risks involving the codeine component.


Q: Will Korylan make me feel sleepy or tired?

Official labeling lists common adverse reactions related to the nervous system. These include drowsiness, lightheadedness, and sedation. These effects are common and are associated with a decrease in alertness.


Q: What are the required storage conditions for Korylan?

Regulatory guidelines mandate that the medicine must be stored at a controlled room temperature (usually between 20 C and 25 C), protected from moisture and excess heat. Due to its composition, official guidelines indicate it should be stored in a secure location and kept strictly out of sight and reach of children.


Q: Is it normal to feel a mild headache after starting Korylan?

Yes, official labeling for the medicine includes headache as a possible adverse reaction that users may experience.


Q: Why do people sometimes stop using Korylan?

Official warnings describe a range of serious risks associated with the medicine, such as life-threatening respiratory depression and acute liver failure. These risks are reasons for discontinuation of the medicine, as detailed in the official safety profile.


Q: Does Korylan have any known effects on mental clarity?

Official labeling states the drug may impair mental abilities and notes confusion as a less common side effect. This relates to potential effects on mental abilities such as concentration and judgment.


Q: Why do official documents mention specific lab tests related to Korylan use?

Regulatory documents recommend monitoring due to the potential risk of Acute Liver Failure (Hepatotoxicity) associated with the acetaminophen component. This risk is dose-dependent and may require specific lab tests to check liver function during use.


Q: Can Korylan change my mood or emotional state?

Official adverse reaction listings include mental depression and confusion (mild) as possible, though less common, effects. These indicate that changes in emotional state or mood may occur.


Q: Is Korylan known to cause skin rashes?

Official labeling warns that the acetaminophen component may cause rare but severe skin reactions. These reactions are described as including skin reddening, rash, and blisters.


Q: How quickly is Korylan eliminated from the body?

Regulatory documents that detail the medicine's action describe that the elimination of the acetaminophen component is primarily through liver metabolism and subsequent renal excretion of metabolites.


Q: What is the difference between the 'on-label' and 'off-label' use mentioned in general discussions about Korylan?

The on-label use is the specific set of indications, doses, and administration methods that have been formally reviewed and approved by the regulatory agency for that medicine. Any other use is considered off-label.


Q: What are the different dosage forms Korylan comes in (e.g., tablet, liquid)?

Official documents state the medicine is available in several oral dosage forms designed for oral administration. These typically include tablets, oral solution, and oral suspension.


Q: Do other medicines make Korylan less effective?

Yes, regulatory information notes that co-administration with certain drugs, specifically CYP2D6 inhibitors, may decrease the conversion of codeine into its active form. This change could risk reduced analgesic efficacy.


Q: Is it possible to become resistant to the effects of Korylan over time?

Official labeling states that repeated use of opioid-containing medicines may lead to the development of physical dependence and tolerance. Tolerance is a condition where a lower response may be observed with the same dose over time.

How should Korylan be stored and disposed of?

How to Store and Dispose of Korylan

Official regulatory guidelines for Korylan (Acetaminophen and Codeine) mandate specific security and environmental conditions, primarily due to the opioid component.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F).
Environmental Keep the medicine in its original container, tightly closed, and protect it from excess heat, moisture, and freezing (do not refrigerate).
Child Safety Korylan must be stored in a secure location and kept strictly out of sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

Disposal must follow specific protocols for controlled substances. The preferred method is to return unused or expired tablets to an authorized drug take-back program or DEA-registered collector. If a take-back option is unavailable, the product must be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a plastic bag, and placed in the household trash. Personal information must be removed from the container before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Korylan found in:

A-Z Index: